Home

Innovative veterinary medicine for better animal health

Through in-house research and pharmaceutical development, a growing product portfolio, and strong partnerships, Intervacc develops and provides veterinary vaccines and medicines that address key needs in animal health.

Our pipeline »

Technology »

Operations »

LATEST PRESS RELEASE: Interim Report January – September 2026»

LATEST REPORT:

Quarterly report Apr–Jun 2026

»

LATEST NEWS BRIEF: New Strangvac data presented at IEVA26 today»

Our veterinary vaccines and medicines



Strangvac®

Strangvac® is our proprietary modern vaccine against strangles, a highly contagious and serious equine disease caused by the bacterium *Streptococcus equi.* Read more »



Piggivac™

Development is underway of an innovative vaccine against infections caused by the bacterium *Streptococcus suis* – one of the most common causes of serious illness and mortality in pigs.Read more »

The product portfolio

In addition to our proprietary vaccine Strangvac®, we sell veterinary products for companion and farm animals in the Scandinavian markets. Read more »

FROM SCIENCE TO VETERINARY BENEFIT

Intervacc is a Swedish growth company in veterinary medicine


Healthcare
Digital Micro Cap Semina
Måndag 9 mars
INTERVACC

STOCKHOLM
CORPORATE
FINANCE
INTERVACC
Stockholm Corporate Fi
Life Science 2026
0:24

CURRENT PRESS RELEASES

View all »

12 Nov 2026
Interim Report January – September 2026»
3 Nov 2026
Real-world Strangvac data shows nearly 100% protection»
15 Sep 2026
Intervacc to present at upcoming International Healthcare Conference»

IN THE CALENDAR

View all »

14–15 NOVEMBER 2026
VeTA Days, Upplands Väsby
4–6 NOVEMBER 2026
AVEF Metz, France.
26–31 OCTOBER 2026
Jönköping Horse Show.
22–23 OCTOBER 2026
Danish Veterinary Congress in Copenhagen, Denmark.
Date Created
2026-09-10